Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast carcinoma in situ.

D W Kinne1, J A Petrek, M P Osborne

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.

Archives of Surgery (Chicago, Ill. : 1960)
|January 1, 1989
PubMed
Summary

In situ breast cancer treatment outcomes show low mortality, with modified radical mastectomy being common. Axillary dissection is not recommended for in situ breast cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ErbB-2 protein levels in healthy, asymptomatic women.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals·2013
Same author

Breast cancer in patients with residual invasive carcinoma is more accurately staged with additive tumor size assessment.

Annals of surgical oncology·2003
Same author

Determination of size in invasive breast carcinoma: pathologic considerations and clinical implications.

American journal of clinical pathology·2002
Same author

Quantifying mammary duct carcinoma in situ: a wild-goose chase?

American journal of clinical pathology·2002
Same author

Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis.

Cancer·2001
Same author

Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization.

The breast journal·2001

Area of Science:

  • Oncology
  • Surgical Oncology
  • Breast Cancer Research

Background:

  • In situ breast cancer management has evolved significantly since the 1970s.
  • Understanding long-term outcomes for ductal and lobular carcinoma in situ is crucial for treatment planning.

Purpose of the Study:

  • To evaluate the long-term outcomes of patients diagnosed with in situ breast cancer between 1970 and 1976.
  • To assess the efficacy of different treatment modalities, including mastectomy and excision.
  • To determine the role of axillary lymph node status in in situ breast cancer prognosis.

Main Methods:

  • Retrospective analysis of 150 patients with in situ breast cancer treated from 1970-1976.
  • Median follow-up of 11.5 years.
  • Separate analysis for subgroups including microinvasion and bilateral disease.

Main Results:

  • Only one patient (out of 150) died of ductal carcinoma in situ; six died of other causes with no evidence of disease.
  • Modified radical mastectomy was performed in 112 cases.
  • Axillary lymph node involvement was rare (1/128 patients), suggesting axillary dissection is not indicated for in situ disease.
  • Patients with microinvasion had a 10% rate of involved nodes and 94% had no evidence of disease.
  • All patients with bilateral disease had no evidence of disease at follow-up.

Conclusions:

  • In situ breast cancer, including ductal and lobular types, has a favorable long-term prognosis with low treatment-related mortality.
  • Modified radical mastectomy was the predominant surgical approach, but outcomes were generally good.
  • Axillary dissection is not indicated for in situ breast cancer due to low rates of nodal metastasis.

Related Experiment Videos